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Abstract 
A radio-analytical RP-HPLC method was developed and validated to support production of the P2X7-
receptor-targeted [11C]GSK1482160 radiopharmaceutical. Method validation included characterization 
of retention times, peak shapes, linearity, accuracy, precision, selectivity, limits of detection and 
quantitation (UV signal), radiochemical stability, as well as analytical method range and robustness. 
The validated radio-HPLC method is suitable for the definition of [11C]GSK1482160 radiochemical 
identity, radiochemical purity as well as molar activity, and is being employed in support of human 
studies with [11C]GSK1482160.  
 
1. Introduction 
The P2X7 receptor is expressed on cells of hematopoietic origin, such as activated macrophages, 
monocytes, and microglia (Adinolfi et al., 2018; Barlett et al., 2014; Collo et al., 1997; Di Virgilio et al., 
2017; Domercq et al., 2013; Sanz et al., 2009; Skaper et al., 2010; Volonte et al., 2012), and is rapidly 
up-regulated by inflammatory stimuli. Thus, the P2X7 receptor appears attractive as a possible 
molecular target for development of diagnostic imaging agents to evaluate and monitor tissue 
inflammation. 
GSK1482160 is a negative allosteric modulator of P2X7 function (Abdi et al., 2010; Ali et al., 2012) with 
documented bioavailability, pharmacokinetics, pharmacodynamics, safety, and tolerability after oral 
administration to humans (Ali et al., 2012). The high affinity of GSK1482160 (Kd = 1.1 nM) for the 
human P2X7 receptor (Territo et al., 2017), coupled with its established human pharmacology (Ali et 
al., 2012), make [11C]GSK1482160 (Gao et al. 2015; Territo et al., 2017), (Figure 1), an attractive 
candidate radiopharmaceutical for assessing whether P2X7 receptor expression can serve as a marker 
for PET detection of regional inflammation.  
We report here the development and validation of a reversed-phase high performance liquid 
chromatography (RP-HPLC) radio-analytical method suitable for pre-release quality control testing of 
[11C]GSK1482160 radiopharmaceutical intended for administration to human research subjects. 
 
2. Materials and Methods 
[11C]GSK1482160 was synthesized following the methods described previously (Gao et al. 2015).  A 
Waters 1524 HPLC Binary System, equipped with both a Waters 2487 UV Detector and a Carroll & 
Ramsey single channel high sensitivity radiation detector, was used to provide a qualitative and 
quantitative determination of [11C]GSK1482160 in radiopharmaceutical samples. The validated radio-
HPLC method employed a C18 Prodigy column, 5 m ODS – 3 V 100 Å (250 x 4.6 mm), eluted 
isocratically with mobile phase, containing 35.6% acetonitrile : 64.4% 20 mM aqueous phosphoric acid 
at a flow rate of 1.80 mL/min (20 µL HPLC sample injections). Non-radioactive GSK1482160 and 
desmethyl-GSK1482160 precursor (Gao et al., 2015) were detected and analyzed based on their UV 
absorbance at 275 nm (the measured λmax value of both GSK1482160 and desmethyl-GSK1482160), 
while [11C]GSK1482160 and radiochemical impurities were detected with the downstream scintillation 
detector. Desmethyl-GSK1482160 precursor and GSK1482160 reference standard solutions were 
prepared at various concentration levels ranging from 0.3 nmol/mL to 15.0 nmol/mL (in the expected 
concentration range of the radiopharmaceutical sample synthesized) to demonstrate analytical HPLC 
method performance.  
Reversed phase high performance liquid chromatography (RP-HPLC) radio-analytical method 
validation included characterization of retention times (tR), peak shapes, linearity, accuracy, precision-
repeatability, selectivity, system suitability, chemical and radiochemical stability, as well as limits of 
detection and quantitation (UV signal) for both desmethyl-GSK1482160 precursor and GSK1482160. 
Data obtained from linearity, accuracy and precision studies was used to assess method range and 
robustness. Molar activity was calculated from the quantity of radioactivity injected and the 
GSK1482160 carrier mass quantified with the UV detector. The method established with the non-
radioactive standards was validated in three production runs of [11C]GSK1482160 radiopharmaceutical 
product, demonstrating tracer identity, chemical and radiochemical purity and radiochemical stability.  
In addition, we report the findings from our subsequent implementation of the method in support of PET 
studies with [11C]GSK1482160 in ten normal human volunteers.  
 
3. Results and Discussion 
A robust reverse phase (C18) HPLC method for [
11C]GSK1482160 was developed and validated, 
employing isocratic elution with a mobile phase of 35.6% acetonitrile : 64.4% 20 mM aqueous 
phosphoric acid. In accordance with USP <1225> Validation of compendial procedures (2018), typical 
analytical performance characteristics along with methods by which it may be measured were assessed 
to demonstrate the suitability of the HPLC analytical procedure. In characterizing the suitability of the 
HPLC method, we took into account the synthetic route to the [11C]GSK1482160 radiopharmaceutical, 
the suitability of the chromatographic conditions, and the HPLC column along with the UV detector 
signal responses.  
USP <1226> Verification of compendial procedures (2018) does not provide specific acceptance 
criteria for the performance characteristics of the radio-analytical HPLC methods due to the fact that the 
verification and validation requirements are based on the complexity of the procedure and the materials 
to which the procedure is applied to. Therefore, our acceptance criteria for the performance 
characteristics of the radio-HPLC analytical method was based on laboratory studies, demonstrating 
the identity, strength, quality and purity of [11C]GSK1482160 radiopharmaceutical produced. Our 
implemented specifications for the product quality include: radiochemical purity ≥ 95%; desmethyl-
GSK1482160 present at ≤ 5% of the UV-detected GSK1482160 mass; radiochemical identity 
established by HPLC retention time within 10% of the reference standard. These specifications are 
consistent with former USP Monographs for other 11C-labeled PET radiopharmaceuticals(e.g., 
[11C]raclopride). Our specification for molar activity was ≥ 0.50 mCi/nmol (≥18.5 MBq/nmol) at 
expiration. At this molar activity limit, the administered mass of GSK1482160 will remain below 20-µg, 
even at the expected maximum administered [11C]GSK1482160 dose of 30 mCi (1.1 GBq). This 
maximal mass dose of GSK1482160 can be regarded as pharmacologically benign, based on the 
reported clinical trial oral dosing of GSK1482160, the associated blood levels of GSK1482160, and the 
reported minimum anticipated biological effect level of 4 ng/mL blood (Ali et al, 2012).     
As such, system suitability testing was performed to verify that the accuracy and precision of the HPLC 
system was adequate for analysis. System parameters such as: resolution (R), tailing factor (T), plate 
count (N) and relative standard deviation (RSD) for ten replicate standard injections of the solution 
containing both analytes (desmethyl-GSK1482160 and GSK1482160) at 100% of the targeted 
concentration (target/nominal concentration of 10.0 nmol/mL) were determined. Selectivity (specificity) 
was demonstrated for both analyte peaks. Desmethyl-GSK1482160 precursor and GSK1482160 peaks 
were found to be well separated, with retention times (tR) of 5.6 and 7.2 minutes, respectively (Figure 
2), and without interference from other chemical entities. The resolution (R) between the two 
components was R > 5. The tailing factor (T) for both desmethyl-GSK1482160 and GSK1482160 
standard was 1 < T < 2. The plate count or theoretical plates (N) were N > 6000.  
Standard samples solutions were prepared at five concentration levels (in the expected 
radiopharmaceutical sample concentration range) with triplicate sample preparation for each 
concentration, in order to establish calibration curves for both components, desmethyl-GSK1482160 
and GSK1482160 respectively (see Appendix A. Supplementary material).  
The minimum level at which both components can be reliably detected, as expressed by Limit of 
Detection (LOD),  was calculated based on the signal-to-noise ratio. Measured signals of known low 
concentration standard solutions were compared to saline blank sample solutions, and the minimum 
concentration at which the analytes could be reliably detected was established. A signal-to-noise ratio 
of 7:1 was considered to be acceptable for establishing LOD (the lowest standard concentration for six 
consecutive standard injections, with an RSD < 10%, was considered to provide reliable detection). The 
Limits of Detection (LOD) were 0.30 nmol/mL for both the desmethyl-GSK1482160 precursor and 
GSK1482160. A signal-to-noise ratio of 13:1 was considered acceptable for establishing the Limits of 
Quantitation (LOQ). The Limit of Quantitation was established according to USP <1225> Validation of 
Compendial Procedures (2018), as the lowest sample concentration that gives a signal-to-noise ratio of 
at least 10:1 (the minimum concentration at which the sample can be reliably quantified), or a peak 
height at least ten times the baseline noise level.  Based on experimental data (Appendix A. 
Supplementary Material), the Limits of Quantitation (LOQ) were 0.60 nmol/mL for both components, 
desmethyl-GSK1482160 precursor and GSK1482160 respectively.  
Method accuracy was demonstrated for desmethyl-GSK1482160 and GSK1482160 by preparing three 
replicate standard sample solutions at three concentration levels over the range of 50% to 150% of the 
nominal sample concentration (of 10.0 nmol/mL). The acceptance criteria as represented by the 
Relative Standard Deviation (RSD) for the three replicate samples was established as less than 5% 
and the mean sample recovery was deemed acceptable within the range of 90% to 110% of the sample 
concentration theoretical value. The RSD for both components was RSD < 5% and the % Average 
Sample Recovery was within the acceptable range (of 90% - 110% of theoretical value) for both 
components (experimental data is included in the Appendix A. Supplementary material).  
The precision-repeatability was demonstrated by performing ten replicate HPLC injections of a standard 
sample solution at the nominal concentration (of 10 nmol/mL) and according to the HPLC method 
procedure. The precision-repeatability acceptance criteria was established by the Relative Standard 
Deviation, as RSD < 5.0% for the retention times, peak heights and peak area responses for both 
components (see Appendix A. Supplementary material).   
Linearity was demonstrated in the sample concentration range of 1 nmol/mL to 15 nmol/mL (for both 
desmethyl-GSK1482160 and GSK1482160). The linearity acceptance criteria was established by the 
correlation coefficient (R2), as R2≥ 0.980 and the y-intercept, as y-intercept < 2% of the target 
concentration area response. The correlation coefficient (R2) calculated at five standard concentration 
levels, was R2 > 0.999, while the y-intercept % of target concentration response was < 2 % for both 
components (see Appendix A. Supplementary material).  
Data obtained during linearity, accuracy and precision determinations were used to assess the range of 
the radio-HPLC analytical method. The analytical method has a suitable level of precision, accuracy 
and linearity in the sample concentration range of 1 nmol/mL to 15 nmol/mL. The HPLC analytical 
method proved to be robust and remained unaffected by small deliberate variations in the procedural 
parameters, or small changes in the chromatographic conditions (e.g., unchanged across various 
batches of the HPLC columns, different HPLC systems, different analysts, minor changes in the 
ambient temperature of ± 2°C, minor mobile phase pH variations of  ± 0.2, minor flow rate variations of 
± 0.1 mL/min). 
In addition, radiotracer identity for the [11C]GSK1482160 radiopharmaceutical was established based on 
demonstrating an HPLC retention time identical to the non-radioactive GSK1482160 standard (Figure 
2, Figure 3). The [11C]GSK1482160, with a retention time of 7.2 minutes, was well resolved from an 
unidentified minor radiochemical impurity (< 5.0 %) with the retention time of 5.2 minutes (Figure 3). We 
have been unable to establish the chemical identity of this radiochemical impurity, as it generates no 
corresponding UV signal on the UV detector. 
The stability of the [11C]GSK1482160 product was demonstrated by repeating the radio-HPLC analysis 
at, or beyond, the radiopharmaceutical’s expiration time (set as no more than one hour from the 
terminal sterilizing filtration). There was no evidence of the degradation of the [11C]GSK1482160 
product at room temperature, with the radiochemical purity always exceeding 95% at the expiration 
time for the validation batches (Table 1). The final formulation of the radiopharmaceutical drug product 
was isotonic sterile saline (0.9% sodium chloride) containing ~5% ethanol. 
Radio-HPLC method validation involving the analysis of the [11C]GSK1482160 from three production 
runs consistently showed the the desmethyl-GSK1482160 precursor to be absent in the final product 
(Figure 4). 
The undesired 11C - isomeric side-product, which arises in small amounts by competitive 11C-
methylation at the side chain amide N position of the desmethyl-GSK1482160 precursor (Figure 1), was 
always effectively removed in the semi-preparative HPLC separation of the production process that 
precedes final [11C]GSK1482160 formulation.  
Radio-HPLC of the isomeric impurity produced (Figure 1) as a minor side-product and isolated as a 
separate fraction after collecting the [11C]GSK1482160 fraction in semi-preparative HPLC shows a 
small quantity of [11C]GSK1482160 at tR = 7.2 minutes, in addition to the isomeric side-product with tR = 
7.9 minutes (Figure 5). Using the validated analytical HPLC method for [11C]GSK1482160 analysis, we 
determined that the 11C-side-product (tR = 7.9 minutes; Figure 5) is well separated from the 
[11C]GSK1482160 product (tR = 7.2 minutes; Figure 3). The final formulated [
11C]GSK1482160 
radiopharmaceutical product never showed evidence of radiochemical contamination by the undesired 
alkylation isomer. 
Repeated chromatographic analyses show no evidence of the GSK1482160 reference standard 
degradation over one year, as well as no evidence of [11C]GSK1482160 degradation over the one-hour 
period prior to its labeled expiration. 
This radio-HPLC method has been fully implemented as part of the quality control procedures for the 
[11C]GSK1482160 synthesized for use in PET imaging with human subjects. In production runs for the 
first ten subjects, [11C]GSK1482160 radiochemical purity averaged 96.25 ± 1.25%, with a molar activity 
average of 0.51 ± 0.1 mCi/nmol (18.9 ± 3.7 MBq/nmol) at the labeled dose expiration time (Table 2).  At 
the time of administration, molar activity averaged 1.03 ± 0.28 mCi/nmol (38.1 ± 10.4 MBq/nmol), with 
doses averaging 26 ± 2 mCi (962 ± 74 MBq). 
 
4. Conclusions 
A reversed phase high performance liquid chromatography (RP-HPLC) radio-analytical method was 
developed, and its performance validated to meet USP guidelines for linearity, accuracy, precision, 
selectivity, limit of detection, limit of quantitation (UV signal), range, and robustness. The analytical 
method is robust and unaffected by small changes in chromatographic conditions.  The performance of 
this radio-analytical method is suitable for pre-release assessment of [11C]GSK1482160 
radiopharmaceutical, defining product radiochemical purity, molar activity, as well as the absence of 
contamination by the desmethyl-GSK1482160 precursor. This radio-HPLC method supports delivery of 
the [11C]GSK1482160 radiopharmaceutical in accordance with the requirements for identity, strength, 
quality and purity outlined in USP <823> Positron emission tomography drugs for compounding, 
investigational, and research uses (2018). 
 
  
Acknowledgements 
This work was supported by Indiana University School of Medicine, Department of Radiology and 
Imaging Sciences and the Renal Imaging Technology Development Program of the IUPUI Research 
Center for Quantitative Renal Imaging. 
 
Appendix A. Supplementary material 
Supplementary data associated with this article can be found in the online version at:  
 
 
References 
 
Abdi, M., Beswick, P., Billinton, A., Chambers, L., Charlton, A., Collins, S., Collis, K., Dean, D., Fonfria, 
E., Gleave, R., Lejeune, C., Livermore, D., Medhurst, S., Michel, A., Moses, A., Page, L., Patel, S., 
Roman, S., Senger, S., Slingsby, B., Steadman, J., Stevens, A. and Walter, D. 2010. Discovery and 
structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 
receptor. Bioorg. Med. Chem. Lett. 20, 5080-5084. 
 
Adinolfi, E., Giuliani, A., De Marchi, E., Pegoraro, A., Orioli, E. and Di Virgilio, F. 2018. The P2X7 
receptor: A main player in inflammation. Biochem. Pharmacol. 151, 234-244. 
 
Ali, Z., Laurijssens, B., Ostenfeld, T., McHugh, S., Stylianou, A., Scott-Stevens, P., Hosking, L., Dewit, 
O., Richardson, J. and Chen, C. 2012. Pharmacokinetic and pharmacodynamic profiling of a P2X7 
receptor allosteric modulator GSK1482160 in healthy human subjects. Br. J. Clin. Pharmacol. 75, 197-
207. 
 
Bartlett, R., Stokes, L. and Sluyter, R. 2014. The P2X7 receptor channel: recent developments and the 
use of P2X7 antagonists in models of disease. Pharmacol. Rev. 66, 638-675. 
 
Collo, G., Neidhart, S., Kawashima, E., Kosco-Vilbois, M., North, R. and Buell, G. 1997. Tissue 
distribution of the P2X7 receptor. Neuropharmacology 36, 1277-1283. 
 
Di Virgilio, F., Dal Ben, D., Sarti, A., Giuliani, A. and Falzoni, S. 2017. The P2X7 receptor in infection 
and inflammation. Immunity 47, 15-31. 
 
Domercq, M., Vazquez-Villoldo, N. and Matute, C. 2013. Neurotransmitter signaling in the 
pathophysiology of microglia. Front. Cell. Neurosci. 7, 1-17. 
 
Gao, M., Wang, M., Green, M., Hutchins, G. and Zheng, Q. 2015. Synthesis of [11C]GSK1482160 as a 
new PET agent for targeting P2X7 receptor. Bioorg. Med. Chem. Lett. 25, 1965-1970. 
 
Sanz, J., Chiozzi, P., Ferrari, D., Colaianna, M., Idzko, M., Falzoni, S., Fellin, R., Trabace, L. and Di 
Virgilio, F. 2009. Activation of microglia by amyloid (beta) requires P2X7 receptor expression. J. 
Immunol. 182, 4378-4385. 
 
Skaper, S., Debetto, P. and Giusti, P. 2010. The P2X7 purinergic receptor: from physiology to 
neurological disorders. FASEB J. 24, 337-345. 
 
Territo, P., Meyer, J., Peters, J., Riley, A., McCarthy, B., Gao, M., Wang, M., Green, M., Zheng, Q. and 
Hutchins, G. 2017. Characterization of 11C-GSK1482160 for targeting the P2X7 receptor as a 
biomarker for neuroinflammation. J. Nucl. Med. 58, 458-465. 
 
USP. 2018. Positron emission tomography drugs for compounding, investigational, and research uses 
<823>. In: USP41-NF36. Rockville, MD. 823, 6629. 
 
USP. 2018. Validation of compendial procedures <1225>. In: USP41-NF36, Rockville, MD. 1225, 7665. 
 
USP. 2018. Verification of compendial procedures <1226>. In: USP41-NF36. Rockville, MD. 1226, 
7671. 
 
Volonte, C., Apolloni, S., D. Skaper, S. and Burnstock, G. 2012. P2X7 receptors: channels, pores and 
more. CNS Neurol. Disord.: Drug Targets. 11, 705-721. 
 
 
 
 
 
Figures 
Figure 1. Synthetic route to the [11C]GSK1482160 radiopharmaceutical (Gao et al., 2015).  
 
Figure 2. HPLC–UV: Example of the separation of desmethyl-GSK1482160 precursor and 
GSK1482160 (tR Desmethyl-GSK1482160 = 5.6 minutes,  tR GSK1482160 = 7.2 minutes). 
 
Figure 3. Radio-HPLC results for a typical [11C]GSK1482160 radiopharmaceutical preparation (tR 
Radiochemical impurity = 5.2 minutes, tR [
11C]GSK1482160 = 7.2 minutes). 
 
Figure 4. HPLC-UV results for a typical [11C]GSK1482160 final product sample (tR GSK1482160 = 7.1 
minutes, sample concentration = 10 nmol/mL). 
 
Figure 5. Radio-HPLC of the isomeric impurity fraction (tR  [
11C]GSK1482160 = 7.2 minutes, tR Isomeric 
impurity = 7.9 minutes). 
 
 
Table 1. Characteristics of three [11C]GSK1482160 validation batches analyzed using the validated 
radio-HPLC analytical method. 
Sample ID 
[11C]GSK1482160  
tR  (minutes) 
[11C]GSK1482160  
Radiochemical purity 
(%) GSK1482160 
reference 
standard tR 
(minutes) 
[11C]GSK1482160 
Molar activity at 
expiration time 
Initial 
analysis 
Repeat 
analysis 
after 
expiration 
time 
Initial 
analysis 
Repeat 
analysis 
after 
expiration 
time 
mCi/nmol MBq/nmol 
110416 GSK-A 7.128 7.126 98.80 98.04 7.097 0.50 18.50 
110716 GSK-A 6.955 7.133 97.00 96.00 7.137 0.52 19.24 
110716 GSK-B 7.137 7.118 96.50 95.74 7.130 0.49 18.13 
Mean 7.073 7.126 97.43 96.59 7.121 0.50 18.62 
STDEV 0.103 0.008 1.210 1.260 0.021 0.015 0.565 
 
  
Table 2. [11C]GSK1482160 study in ten volunteers used for PET imaging. 
Sample ID 
Radiochemi
cal purity 
(%) 
GSK mass 
(nmol/mL) 
Sample 
volume (mL) 
Activity at 
EOS (mCi) 
Activity at 
expiration 
(mCi/mL) 
Molar 
activity at 
expiration 
(mCi/nmol) 
081817 GSK-A 97.40 3.90 11.30 131.00 1.95 0.50 
083017 GSK-A 96.80 3.56 10.90 125.50 1.81 0.51 
091517 GSK-A 95.30 3.70 10.80 167.30 1.85 0.50 
092817 GSK-A 96.40 5.25 11.20 175.70 2.64 0.50 
100217 GSK-A 97.40 4.47 10.60 121.80 2.30 0.51 
100317 GSK-A 96.30 5.36 11.20 187.60 2.73 0.51 
102717 GSK-A 95.00 4.45 10.30 241.00 2.28 0.51 
110917 GSK-A 97.20 4.36 10.30 159.00 2.27 0.52 
111017 GSK-A 97.50 4.30 10.00 121.90 2.20 0.51 
112017 GSK-A 96.60 10.00 10.50 214.00 5.18 0.52 
Mean 96.59 4.93 10.71 164.48 2.52 0.51 
STDEV 0.87 1.87 0.44 41.21 0.98 0.01 
 
 
 
 
 
 
 
 
 
 Highlights 
 
•  A radio-analytical method was validated for the [11C]GSK1482160 radiopharmaceutical. 
 
• The method proved to be robust and unaffected by small changes in the chromatographic conditions. 
 
• The [11C]GSK1482160 radiopharmaceutical exhibits high radiochemical stability. 
 
• [11C]GSK1482160 radiopharmaceutical can be delivered in accordance with USP <823> require-
ments. 
 
• The P2X7-receptor-targeted [11C]GSK1482160 meets release criteria for human use. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
